10-K Decoder · All companies

Ultragenyx Pharmaceutical Inc.

RARE · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026

Open the dashboardInfographicSummary

FY2025 key figures

$FY2025FY2024Change
Revenue$673M$560M+20.2%
Operating income−$535M−$536M+0.2%
Net income−$575M−$569M−1.1%

Latest quarter: Q3 2026

Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 4, 2026

$Q3 2026Year earlierChange
Revenue$173M$160M+8.1%
Operating income−$110M−$171M+35.7%
Net income−$118M−$180M+34.4%

Q3 2026 dashboardQ3 2026 infographic

Questions

What was Ultragenyx Pharmaceutical's revenue in FY2025?
$673M in FY2025 (Fiscal year ended Dec 31, 2025), +20.2% vs $560M a year earlier, per its 10-K filed Feb 2026.
Was Ultragenyx Pharmaceutical profitable in FY2025?
No: net income was −$575M and operating income −$535M in FY2025.
What was Ultragenyx Pharmaceutical's revenue in Q3 2026?
$173M (+8.1% vs a year earlier), per its Form 10-Q filed Nov 4, 2026.